Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lyell Immunopharma

Explore full profile

Operator of a biotechnology company that develops cellular therapies to cure cancer

San Francisco, United StatesFounded 2018Biotech & Life Sciences
Valuation $103M Market cap · Aug/2026
Revenue $36K Latest reported FY

At a glance

Status
Listed
Founded
2018
Headquarters
San Francisco, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • University of Washington

Talent

Book a demo to see the people
Employees mapped 233 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99.9%
🇯🇵 Japan0.6%
2 countries shown
Web traffic by country
7.4K monthly visits
across markets
🇺🇸 United States77%
🇮🇳 India13.5%
🇨🇦 Canada9.5%
Top 3 markets shown

Patents

Estimated portfolio value
$8M

35 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Lyell Immunopharma was the backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Lyell Immunopharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Lyell Immunopharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Lyell Immunopharma's portfolio, mapped.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Lyell Immunopharma on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Lyell Immunopharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles